Tirzepatide, a recently approved medication, is generating excitement as a potential treatment for individuals diagnosed with diabetes of type 2. Unlike common diabetes medications , it operates through a dual mechanism, targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. Clinical trials have illustrat